FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141703599> ?p ?o ?g. }

• W2141703599 endingPage "1332" @default.
• W2141703599 startingPage "1332" @default.
• W2141703599 abstract "Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition.To evaluate short-term effects of tolvaptan when added to standard therapy in patients hospitalized with heart failure.Two identical prospective, randomized, double-blind, placebo-controlled trials at 359 sites in North America, South America, and Europe were conducted during the inpatient period of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) between October 7, 2003, and February 3, 2006. A total of 2048 (trial A) and 2085 (trial B) patients hospitalized with heart failure and congestion were studied.Patients were randomized to receive either tolvaptan (30 mg/d) or matching placebo, within 48 hours of admission.Primary end point was a composite of changes in global clinical status based on a visual analog scale and body weight at day 7 or discharge if earlier. Secondary end points included dyspnea (day 1), global clinical status (day 7 or discharge), body weight (days 1 and 7 or discharge), and peripheral edema (day 7 or discharge).Rank sum analysis of the composite primary end point showed greater improvement with tolvaptan vs placebo (trial A, mean [SD], 1.06 [0.43] vs 0.99 [0.44]; and trial B, 1.07 [0.42] vs 0.97 [0.43]; both trials P<.001). Mean (SD) body weight reduction was greater with tolvaptan on day 1 (trial A, 1.71 [1.80] vs 0.99 [1.83] kg; P<.001; and trial B, 1.82 [2.01] vs 0.95 [1.85] kg; P<.001) and day 7 or discharge (trial A, 3.35 [3.27] vs 2.73 [3.34] kg; P<.001; and trial B, 3.77 [3.59] vs 2.79 [3.46] kg; P<.001), whereas improvements in global clinical status were not different between groups. More patients receiving tolvaptan (684 [76.7%] and 678 [72.1%] for trial A and trial B, respectively) vs patients receiving placebo (646 [70.6%] and 597 [65.3%], respectively) reported improvement in dyspnea at day 1 (both trials P<.001). Edema at day 7 or discharge improved significantly with tolvaptan in trial B (P = .02) but did not reach significance in trial A (P = .07). Serious adverse event frequencies were similar between groups, without excess renal failure or hypotension.In patients hospitalized with heart failure, oral tolvaptan in addition to standard therapy including diuretics improved many, though not all, heart failure signs and symptoms, without serious adverse events.clinicaltrials.gov Identifier: NCT00071331" @default.
• W2141703599 created "2016-06-24" @default.
• W2141703599 creator A5011293667 @default.
• W2141703599 creator A5014193048 @default.
• W2141703599 creator A5022983534 @default.
• W2141703599 creator A5033193895 @default.
• W2141703599 creator A5036821495 @default.
• W2141703599 creator A5051961415 @default.
• W2141703599 creator A5054084408 @default.
• W2141703599 creator A5080222829 @default.
• W2141703599 creator A5085843860 @default.
• W2141703599 creator A5088186128 @default.
• W2141703599 creator A5090348471 @default.
• W2141703599 creator A5091233742 @default.
• W2141703599 date "2007-03-28" @default.
• W2141703599 modified "2023-10-17" @default.
• W2141703599 title "Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure<SUBTITLE>The EVEREST Clinical Status Trials</SUBTITLE>" @default.
• W2141703599 cites W1875039943 @default.
• W2141703599 cites W1970134098 @default.
• W2141703599 cites W1975971363 @default.
• W2141703599 cites W1988232724 @default.
• W2141703599 cites W1993823264 @default.
• W2141703599 cites W1996945315 @default.
• W2141703599 cites W1997638871 @default.
• W2141703599 cites W2003816596 @default.
• W2141703599 cites W2018202908 @default.
• W2141703599 cites W2021559932 @default.
• W2141703599 cites W2042714602 @default.
• W2141703599 cites W2049574314 @default.
• W2141703599 cites W2059717547 @default.
• W2141703599 cites W2080432415 @default.
• W2141703599 cites W2086378904 @default.
• W2141703599 cites W2110289049 @default.
• W2141703599 cites W2112636786 @default.
• W2141703599 cites W2119875370 @default.
• W2141703599 cites W2120040647 @default.
• W2141703599 cites W2120934972 @default.
• W2141703599 cites W2126271215 @default.
• W2141703599 cites W2133579136 @default.
• W2141703599 cites W2137317533 @default.
• W2141703599 cites W2138839431 @default.
• W2141703599 cites W2154845941 @default.
• W2141703599 cites W2164846898 @default.
• W2141703599 cites W2164902492 @default.
• W2141703599 cites W2169560588 @default.
• W2141703599 cites W2268092567 @default.
• W2141703599 cites W2342338671 @default.
• W2141703599 cites W2497721881 @default.
• W2141703599 cites W2606269269 @default.
• W2141703599 cites W2615043561 @default.
• W2141703599 doi "https://doi.org/10.1001/jama.297.12.1332" @default.
• W2141703599 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17384438" @default.
• W2141703599 hasPublicationYear "2007" @default.
• W2141703599 type Work @default.
• W2141703599 sameAs 2141703599 @default.
• W2141703599 citedByCount "778" @default.
• W2141703599 countsByYear W21417035992012 @default.
• W2141703599 countsByYear W21417035992013 @default.
• W2141703599 countsByYear W21417035992014 @default.
• W2141703599 countsByYear W21417035992015 @default.
• W2141703599 countsByYear W21417035992016 @default.
• W2141703599 countsByYear W21417035992017 @default.
• W2141703599 countsByYear W21417035992018 @default.
• W2141703599 countsByYear W21417035992019 @default.
• W2141703599 countsByYear W21417035992020 @default.
• W2141703599 countsByYear W21417035992021 @default.
• W2141703599 countsByYear W21417035992022 @default.
• W2141703599 countsByYear W21417035992023 @default.
• W2141703599 crossrefType "journal-article" @default.
• W2141703599 hasAuthorship W2141703599A5011293667 @default.
• W2141703599 hasAuthorship W2141703599A5014193048 @default.
• W2141703599 hasAuthorship W2141703599A5022983534 @default.
• W2141703599 hasAuthorship W2141703599A5033193895 @default.
• W2141703599 hasAuthorship W2141703599A5036821495 @default.
• W2141703599 hasAuthorship W2141703599A5051961415 @default.
• W2141703599 hasAuthorship W2141703599A5054084408 @default.
• W2141703599 hasAuthorship W2141703599A5080222829 @default.
• W2141703599 hasAuthorship W2141703599A5085843860 @default.
• W2141703599 hasAuthorship W2141703599A5088186128 @default.
• W2141703599 hasAuthorship W2141703599A5090348471 @default.
• W2141703599 hasAuthorship W2141703599A5091233742 @default.
• W2141703599 hasBestOaLocation W21417035991 @default.
• W2141703599 hasConcept C126322002 @default.
• W2141703599 hasConcept C142724271 @default.
• W2141703599 hasConcept C164705383 @default.
• W2141703599 hasConcept C168563851 @default.
• W2141703599 hasConcept C170493617 @default.
• W2141703599 hasConcept C197934379 @default.
• W2141703599 hasConcept C203092338 @default.
• W2141703599 hasConcept C204787440 @default.
• W2141703599 hasConcept C27081682 @default.
• W2141703599 hasConcept C2776370428 @default.
• W2141703599 hasConcept C2776885963 @default.
• W2141703599 hasConcept C2777482430 @default.
• W2141703599 hasConcept C2778198053 @default.
• W2141703599 hasConcept C2779881253 @default.
• W2141703599 hasConcept C2780615674 @default.
• W2141703599 hasConcept C535046627 @default.

• next